# Retatrutide Prescribed

> A handcrafted reading room for the triple-agonist literature — what the trials show, why no clinician can write a script for it yet, and what that gap will look like for visitors when it finally closes.

## Pages

- [Retatrutide Prescribed — A careful, independent reading of an investigational triple agonist](/index.md): A hand-bound reading of the retatrutide (LY3437943) research literature: what the Phase 2 and Phase 3 trials show, why no clinician can write a prescription for it today, and what visitors should understand before reading further.
- [Retatrutide reported effects and safety — what trials found and what people report](/effects.md): Retatrutide effects and safety: what Phase 2 and Phase 3 trials documented, what the research-use community reports (labeled anecdotal), and cited cautions from the trial record.
- [The retatrutide research record — mechanism, Phase 2, and Phase 3](/research.md): A careful editorial walk through retatrutide's mechanism of triple agonism, the Phase 2 obesity / type-2-diabetes / MASLD readouts, and the Phase 3 TRIUMPH program as it currently stands.
- [Retatrutide dosing in clinical-trial context — doses studied, titration, pharmacokinetics](/dosage.md): What doses of retatrutide have been studied in Phase 1, Phase 2, and Phase 3 trials, the titration schedules used to manage tolerability, and the pharmacokinetics that justify a weekly schedule. Trial-context only — retatrutide is investigational.
- [Retatrutide FAQ — prescriptions, compounding, side effects, and what the trials show](/faq.md): Honest answers to the questions readers ask about retatrutide: can it be prescribed, when might it be approved, what do the trials show, what are the side effects, and how it compares with other incretin-pathway molecules.
- [References — the published retatrutide trial record](/references.md): Full citation list for the retatrutide research literature referenced across this site: NEJM, Lancet, Nature Medicine, Cell Discovery, Cell Metabolism, ClinicalTrials.gov, and Phase 3 topline disclosures.
- [About Retatrutide Prescribed — editorial standards and disclosure](/about.md): Retatrutide Prescribed is an independent editorial reading room for the published retatrutide research literature.
- [Contact Retatrutide Prescribed](/contact.md): How to reach the editorial team behind Retatrutide Prescribed. We respond to factual corrections, source-material additions, and reader questions about the published trial record. We do not provide medical advice.